This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Draft Hepatitis C Screening Recommendations From USPSTF Open for Review
By Matt Brown
"In plain terms, we give a B recommendation, recommending this service for testing for hepatitis C virus in high-risk groups," LeFevre told AAFP News Now. "Part two -- a C recommendation -- is that we believe there is a small net benefit of testing the so-called 'cohort approach.'"
LeFevre, a family physician from Columbia, Mo., said the only real difference between the high-risk and cohort groups is the prevalence of the disease.
- The U.S. Preventive Services Task Force (USPSTF) is seeking comment on new draft recommendations proposing routine screening for hepatitis C virus (HCV) infection in high-risk adults.
- In August, the CDC formally expanded its recommendations on screening for HCV infection to include all persons born between 1945 and 1965. The USPSTF says there is a small net benefit to this so-called "cohort approach."
- The comment period on the USPSTF recommendations ends Dec. 24.
LeFevre said it is also important to note that, three-quarters of the people in the United States who are currently infected with HCV are in the 1945-1965 birth cohort.
"So if a family physician wanted to make it easy -- and I wouldn't fault people for this -- and test everybody in (that birth) cohort, then they'd only need to worry about IV drug use in the younger age group, as well as anyone who had a blood transfusion prior to 1992," he said. "Simply put, they should consider (screening) people born between 1945 and 1965 who don't fall into the first category, but understand the yield on that is going to be smaller."
LeFevre said that because some people may not be sure if they had a transfusion before 1992, FPs may need to ask a few more questions.
"Maybe (the patient) was in a car accident and they came in to the emergency room and were hospitalized and they think, 'Maybe I did get blood, but gosh, that was 30 years ago, and I don't really know whether I got blood or not,'" he said. "And that's a little bit harder, but 1992 was when we started testing the blood supply."
With regard to treatment options, LeFevre said antiviral treatment regimens for chronic HCV infection are producing a significantly higher percentage of people with a sustained viral load reduction than in 2004, the last time the task force updated its recommendation.
"The treatments we have available are much more effective at reducing viral load to non-detectable," he said. "So the assumption -- and there are some data supporting this -- is that people with a sustained reduction will also have fewer complications. Although the problem, of course, is that it takes longer term follow up than we have with these drugs to know for sure that it will translate into health benefits."
LeFevre also noted that, unlike an HIV infection, the probability of experiencing bad health outcomes from HCV is fairly small.
"There are people who have chronic HVC infections who we will end up finding and treating, who would actually never have had any of the serious complications -- end-stage liver disease, cirrhosis, cancer of the liver," he said, "whereas with an HIV infection, the percentage of people who experience bad health outcomes is much higher."
The draft recommendations will be open for public comment until Dec. 24 at 5 p.m. EDT.
The AAFP is reviewing the draft recommendations and will update its own 2004 HVC recommendations after the USPSTF publishes its final conclusions in 2013.